Study supports Genomic Health's Oncotype DX breast cancer test
This article was originally published in Clinica
Executive Summary
A study has found that using Genomic Health's Oncotype DX breast cancer recurrence test, as well as a website that provides cancer treatment guidance, provides better prognostic information than the online tool alone, in patients with negative or up to three positive nodes.